- RecruitingPHASE3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
This study is looking into a new medication, rilzabrutinib, for adults with a condition called IgG4-related disease. It compares the medication to a dummy pill to see if it's safe and helps control the disease over 52 weeks.
For: Immunoglobulin G4 Related DiseaseUnited States · Argentina · Belgium - Active not recruitingPHASE3
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
This study tested a new medicine, rilzabrutinib, for adults and teenagers with a blood condition called Immune Thrombocytopenia (ITP). It aimed to see if the medicine could help increase platelet counts, which are important for stopping bleeding.
For: Immune ThrombocytopeniaUnited States · Argentina · Australia - Active not recruitingPHASE2
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
This study is looking into a new medication called rilzabrutinib for adults in the UK with warm autoimmune hemolytic anemia (wAIHA). It will check if the treatment is safe, how well it works, and how the body handles it. Participants will take the medication by mouth.
For: Warm Autoimmune Hemolytic Anemia (wAIHA)United States · Austria · China - RecruitingPHASE3
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
This study looks at a new drug, Rilzabrutinib, for people aged 10-65 with sickle cell disease. We'll see how well it works and if it's safe compared to a dummy pill to help reduce painful crises.
For: Sickle Cell DiseaseUnited States · Belgium · Brazil - RecruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
This study is looking at new medicines (frexalimab, brivekimig, or rilzabrutinib) for kidney conditions called Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD). It aims to see if these medicines are safe and can help improve kidney function compared to a dummy drug.
For: Focal Segmental Glomerulosclerosis · Glomerulonephritis Minimal LesionUnited States · Argentina · Australia - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of Rilzabrutinib (PRN1008), an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenia
This study is testing a new oral medicine, Rilzabrutinib, for adults with a blood condition called Immune Thrombocytopenia (ITP). It aims to see if the medicine is safe, how much to give, and if it helps increase platelet counts to reduce bleeding.
For: Immune ThrombocytopeniaCzechia · Netherlands · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP).
This study is testing a new medicine called rilzabrutinib for adults with a blood condition called Immune Thrombocytopenia (ITP). It compares the new medicine to a dummy treatment to see if it can help increase blood platelet counts and improve quality of life.
For: Immune Thrombocytopenia (ITP)Hungary · Spain · Italy